BACKGROUND: Limited information exists on the intermediate-term graft patency and 5-year clinical outcomes of patients receivingsaphenous vein grafts with multiple (m-SVG) versus single distal targets (s-SVG) during coronary artery bypass graft (CABG) surgery in the current era. METHODS AND RESULTS: We studied the association of the use of m-SVG versus s-SVG conduits with 1-year SVG failure (defined as ≥75% angiographic stenosis) and 5-year clinical events (death; death or myocardial infarction [MI]; and death, MI, or revascularization) in 3014 patients undergoing their first CABG surgery enrolled in the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV. Of 3014 patients enrolled in PREVENT IV, 1045 (34.7%) had ≥1 m-SVGs during CABG. Vein graft failure at 1-year was higher for m-SVG compared with s-SVG (adjusted odds ratio 1.24, 95% confidence interval 1.03 to 1.48). At 5 years, the adjusted composite of death, MI (including perioperative MI), or revascularization (hazard ratio 1.15, 95% confidence interval 1.00 to 1.31) and death or MI (hazard ratio 1.21, 95% confidence interval 1.03 to 1.43) were significantly higher in patients receiving m-SVGs. CONCLUSIONS: In patients undergoing first CABG surgery, the use of m-SVG was associated with a higher 1-year vein graft failure rate and trends toward worse clinical outcomes. Additional studies are needed to better understand the most appropriate conduit to improve long-term graft patency and clinical outcomes of patients undergoing CABG surgery. In the meantime, these data should encourage the use of s-SVG over m-SVG when feasible.
RCT Entities:
BACKGROUND: Limited information exists on the intermediate-term graft patency and 5-year clinical outcomes of patients receiving saphenous vein grafts with multiple (m-SVG) versus single distal targets (s-SVG) during coronary artery bypass graft (CABG) surgery in the current era. METHODS AND RESULTS: We studied the association of the use of m-SVG versus s-SVG conduits with 1-year SVG failure (defined as ≥75% angiographic stenosis) and 5-year clinical events (death; death or myocardial infarction [MI]; and death, MI, or revascularization) in 3014 patients undergoing their first CABG surgery enrolled in the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV. Of 3014 patients enrolled in PREVENT IV, 1045 (34.7%) had ≥1 m-SVGs during CABG. Vein graft failure at 1-year was higher for m-SVG compared with s-SVG (adjusted odds ratio 1.24, 95% confidence interval 1.03 to 1.48). At 5 years, the adjusted composite of death, MI (including perioperative MI), or revascularization (hazard ratio 1.15, 95% confidence interval 1.00 to 1.31) and death or MI (hazard ratio 1.21, 95% confidence interval 1.03 to 1.43) were significantly higher in patients receiving m-SVGs. CONCLUSIONS: In patients undergoing first CABG surgery, the use of m-SVG was associated with a higher 1-year vein graft failure rate and trends toward worse clinical outcomes. Additional studies are needed to better understand the most appropriate conduit to improve long-term graft patency and clinical outcomes of patients undergoing CABG surgery. In the meantime, these data should encourage the use of s-SVG over m-SVG when feasible.
Authors: Kim A Eagle; Robert A Guyton; Ravin Davidoff; Fred H Edwards; Gordon A Ewy; Timothy J Gardner; James C Hart; Howard C Herrmann; L David Hillis; Adolph M Hutter; Bruce Whitney Lytle; Robert A Marlow; William C Nugent; Thomas A Orszulak Journal: Circulation Date: 2004-10-05 Impact factor: 29.690
Authors: John H Alexander; T Bruce Ferguson; Diane M Joseph; Michael J Mack; Randall K Wolf; C Michael Gibson; Daniel Gennevois; Todd J Lorenz; Robert A Harrington; Eric D Peterson; Kerry L Lee; Robert M Califf; Nicholas T Kouchoukos Journal: Am Heart J Date: 2005-10 Impact factor: 4.749
Authors: Connie N Hess; Renato D Lopes; C Michael Gibson; Rebecca Hager; Daniel M Wojdyla; Brian R Englum; Michael J Mack; Robert M Califf; Nicholas T Kouchoukos; Eric D Peterson; John H Alexander Journal: Circulation Date: 2014-09-26 Impact factor: 29.690
Authors: Brian C Cooley; Jose Nevado; Jason Mellad; Dan Yang; Cynthia St Hilaire; Alejandra Negro; Fang Fang; Guibin Chen; Hong San; Avram D Walts; Robin L Schwartzbeck; Brandi Taylor; Jan D Lanzer; Andrew Wragg; Abdalla Elagha; Leilani E Beltran; Colin Berry; Robert Feil; Renu Virmani; Elena Ladich; Jason C Kovacic; Manfred Boehm Journal: Sci Transl Med Date: 2014-03-12 Impact factor: 17.956
Authors: Mario Gaudino; Antonino Di Franco; John H Alexander; Faisal Bakaeen; Natalia Egorova; Paul Kurlansky; Andreas Boening; Joanna Chikwe; Michelle Demetres; Philip J Devereaux; Anno Diegeler; Arnaldo Dimagli; Marcus Flather; Irbaz Hameed; Andre Lamy; Jennifer S Lawton; Wilko Reents; N Bryce Robinson; Katia Audisio; Mohamed Rahouma; Patrick W Serruys; Hironori Hara; David P Taggart; Leonard N Girardi; Stephen E Fremes; Umberto Benedetto Journal: Eur Heart J Date: 2021-12-28 Impact factor: 29.983